Zogenix soars on Phase III data for Dravet syndrome candidate
By Chris Lieu | Sep 29, 2017 | 11:08 PM GMT
Zogenix Inc. (NASDAQ:ZGNX) rocketed $22.17 (172%) to $35.05 on Friday, adding $550 million in market cap, after reporting that ZX008 as adjunctive therapy met the primary endpoint in the Phase III Study 1 to treat
Read the full 350 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury